Gardasil’s Long Shadow of Autoimmunity Confirmed — Again — by New Study

Girls and young women experiencing complications from Merck’s Gardasil HPV vaccine show symptoms and biological markers of autoimmune conditions, according to a new study published in The Journal of Autoimmunity.

Before experimental COVID-19 shots started taking serious vaccine injuries to new and shocking heights, Merck’s aggressively marketed human papillomavirus (HPV) vaccine — the quadrivalent Gardasil jab fast-tracked in 2006 for girls and later also for boys — earned a reputation for being one of the most dangerous vaccines ever approved.

Safety signals were already evident during Gardasil’s clinical trials, and by 2013, researchers were noting the “unusually high frequency of adverse reactions related to HPV vaccines reported worldwide.”

That year, Gardasil’s disproportionately harmful impact — even when compared to other shots that are far from benign — was responsible in the U.S. for three-fifths of all serious vaccine reactions reported in young women under age 30, including 64% of deaths and 81% of cases of permanent disability.

Yet in 2014, the U.S. Food and Drug Administration (FDA) went ahead and approved Gardasil’s equally treacherous successor, the nine-valent Gardasil 9, and in 2016 — when GlaxoSmithKline (GSK) withdrew its poorly competing bivalent HPV vaccine Cervarix from the U.S. market — Gardasil 9 became “the only game in town.”

Currently, Gardasil 9 is FDA-approved for males and females ages 9 through 45 years.

Gardasil’s Long Shadow of Autoimmunity Confirmed — Again — by New Study • Children's Health Defense (childrenshealthdefense.org)